Yokohama, Japan, Munich, Germany, and Allendale, New Jersey, USA. January 6, 2025
Altaris, LLC (collectively with its managed funds, “Altaris”) announced today that it completed the acquisition of Minaris Regenerative Medicine (Minaris Regenerative Medicine, LLC in the United States, Minaris Regenerative Medicine Co., Ltd. in Japan, Minaris Regenerative Medicine GmbH in Germany, and along with its subsidiaries, “Minaris”) from Resonac Corporation, a subsidiary of Resonac Holdings Corporation (TYO: 4004) (“Resonac”). Minaris will be headquartered in the United States and will operate as a wholly owned portfolio company of Altaris.
Minaris is a pure play cell therapy contract development and manufacturing organization (“CDMO”) that provides autologous and allogeneic manufacturing services for pharmaceutical and biotech customers. Founded in 1999 as Progenitor Cell Therapy, Minaris has been a pioneer in the field, manufacturing pivotal study batches for Dendreon’s Provenge®, the first cell therapy approved for cancer treatment, and contributing to the development of many cell therapy products that are on the market today. Minaris has more than 500 employees and operates six facilities, three of which have been approved for the manufacture of commercially approved products, across the United States, Germany, and Japan.
This transaction marks a significant milestone in Altaris’ strategic initiative within the cell therapy sector, which is focused on delivering life-changing therapies to patients at scale. With a 20+ year track record as a responsible owner of healthcare companies, including 11 medical product CDMOs, Altaris is well positioned to steward Minaris as it transitions to being an independent pharma services company.
Advisors
J.P. Morgan served as financial advisor and Kirkland & Ellis LLP acted as legal counsel for Altaris. BofA Securities served as financial advisor and TMI Associates acted as legal advisor to Resonac.
About Altaris
Altaris is an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry. Since its inception in 2003, Altaris has invested in more than 50 companies across a range of healthcare subsectors, with a consistent goal of delivering value to the healthcare system and generating attractive financial returns for investors. Altaris is headquartered in New York City and manages $10 billion of equity capital. For more information, please visit www.altariscap.com.